CI Investments Inc. Grows Stock Holdings in Hims & Hers Health, Inc. $HIMS

CI Investments Inc. lifted its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 9.5% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 226,145 shares of the company’s stock after purchasing an additional 19,633 shares during the period. CI Investments Inc.’s holdings in Hims & Hers Health were worth $4,695,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in HIMS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Hims & Hers Health by 23.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock valued at $12,373,000 after buying an additional 78,543 shares during the period. Geneos Wealth Management Inc. acquired a new stake in Hims & Hers Health in the first quarter worth about $30,000. EverSource Wealth Advisors LLC grew its position in Hims & Hers Health by 273.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock worth $47,000 after purchasing an additional 687 shares during the last quarter. Amundi increased its position in shares of Hims & Hers Health by 5.3% in the 2nd quarter. Amundi now owns 10,296 shares of the company’s stock valued at $489,000 after acquiring an additional 522 shares during the period. Finally, California Public Employees Retirement System increased its holdings in shares of Hims & Hers Health by 9.5% in the second quarter. California Public Employees Retirement System now owns 338,620 shares of the company’s stock valued at $16,880,000 after purchasing an additional 29,471 shares during the period. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Price Performance

HIMS opened at $32.67 on Friday. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $70.43. The stock’s 50-day moving average price is $30.69 and its 200 day moving average price is $26.33. The firm has a market cap of $7.56 billion, a price-to-earnings ratio of -362.99, a PEG ratio of 89.16 and a beta of 2.35. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The company had revenue of $608.10 million for the quarter, compared to analyst estimates of $616.84 million. During the same period in the previous year, the firm earned $0.20 earnings per share. The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. As a group, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.03 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on HIMS. Truist Financial boosted their target price on shares of Hims & Hers Health from $18.00 to $23.00 and gave the company a “hold” rating in a research report on Friday, May 22nd. TD Cowen cut their price target on shares of Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a report on Friday, March 27th. UBS Group set a $23.00 target price on Hims & Hers Health in a report on Friday, May 22nd. Wall Street Zen downgraded shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Zacks Research upgraded Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. Four research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $31.17.

Insiders Place Their Bets

In other news, insider Patrick Harrison Carroll sold 23,726 shares of the company’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $35.00, for a total value of $830,410.00. Following the completion of the sale, the insider directly owned 181,861 shares of the company’s stock, valued at approximately $6,365,135. This represents a 11.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 7,163 shares of the stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $36.49, for a total value of $261,377.87. Following the sale, the chief financial officer directly owned 284,321 shares of the company’s stock, valued at $10,374,873.29. The trade was a 2.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 83,126 shares of company stock worth $2,711,339. Corporate insiders own 11.76% of the company’s stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.